[{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Approved","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Douglas CDMO \/ Douglas Pharmaceuticals Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Douglas CDMO \/ Douglas Pharmaceuticals Ltd"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Not Applicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Not Applicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lopinavir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Douglas CDMO \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"14","companyTruncated":"Douglas CDMO \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Douglas CDMO \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Douglas CDMO \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Douglas CDMO

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Ketamine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : R-107 (ketamine) is an oral NMDA receptor negative allosteric modulator, small molecule drug candidate, which is being evaluated for the treatment of treatment-resistant depression.

                          Brand Name : R-107

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 25, 2024

                          Lead Product(s) : Ketamine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Douglas CDMO

                          02

                          Details : Under the license agreement with Douglas, Dare will be responsible for advancing the development of R-131-2 (Lopinavir/Ritonavir) in the U.S. for the treatment for cervical intraepithelial neoplasia.

                          Brand Name : R-131-2

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 27, 2023

                          Lead Product(s) : Lopinavir,Ritonavir

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : Daré Bioscience

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          Douglas CDMO

                          03

                          Lead Product(s) : Ketamine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance ...

                          Brand Name : R-107

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 26, 2023

                          Lead Product(s) : Ketamine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Douglas CDMO

                          04

                          Details : Upsher-Smith's product is AB2-rated to the branded product, Absorica® (isotretinoin) capsules. Isotretinoin capsules are a generic version of ABSORICA® indicated for the treatment of severe recalcitrant nodular acne.

                          Brand Name : Isotretinoin-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 25, 2021

                          Lead Product(s) : Isotretinoin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Recipient : Upsher-Smith Laboratories

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Douglas CDMO

                          05

                          Lead Product(s) : Ketamine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.

                          Brand Name : R-107

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 15, 2021

                          Lead Product(s) : Ketamine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Douglas CDMO